Forget Nasdaq. China’s biotechs with blockbuster IPO dreams are switching focus to Hong Kong
On Monday, the Hong Kong exchange is set to open its doors and listings to companies with no revenue, and a lineup of biotech unicorns …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
